A novel ROCK inhibitor: off-target effects of metformin

Creative Commons License

ÖZDEMİR A., ARK M.

TURKISH JOURNAL OF BIOLOGY, cilt.45, sa.1, ss.35-45, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.3906/biy-2004-12
  • Dergi Adı: TURKISH JOURNAL OF BIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.35-45
  • Anahtar Kelimeler: Connectivity MAP, Rho kinase, metformin, off-target effect, oral antidiabetics, RHO-ASSOCIATED KINASE, DRUG-TARGET, CANCER, CYTOSKELETON, REGULATOR
  • Gazi Üniversitesi Adresli: Evet

Özet

In drug discovery, most small molecules cannot cross many stages, only a few can become drug candidates. Once the drug molecule is approved and marketed, nontarget effects that are not easily distinguishable from the actual target of the drugs might be evaluated. This situation restricts the treatment. Thus, the discovery of new drugs is a very long and expensive process. In recent years, without developing new drugs, the approach of using different and new target molecules in new indications apart from the indications of licensed drug molecules has gained importance.